Respiratory tract infections including acute

This preview shows page 100 - 102 out of 142 pages.

respiratory tract infections including acute sinusitis, acute exacerbations of chronic bronchitis, and pneumonia, skin/skin structure infections , bone and joint infections , infectious diarrhea , complicated intraabdominal infections (with metronidazole), typhoid fever. Post-exposure prophylaxis of inhalational anthrax. Cutaneous anthrax. Tx and prophylaxis of plague.IVFebrile neutropenia. Unlabeled Use: Acute pulmonaryexacerbations in cystic fibrosisInhibits bacterial DNA synthesis by inhibiting DNA gyrase enzyme. Therapeutic Effects: Death of susceptible bacteria. Spectrum: Active against gram + pathogensH/o myasthenia gravis, use with tizanidine; OB: Do not use unless potential benefit outweighs potential fetal risk; Pedi: Use only if no alternatives in children 1– 17 yrs due to possible arthropathyElevated ICP, diarrhea, nausea, hepatotoxicity, anaphylaxis, c diff , may cause↑ serum AST, ALT, LDH, bilirubin, and alkaline phosphatase. May also cause ↑ or ↓glucose. Cystalluria, dizziness, drowsiness, prevent phototoxicity reactionsAssess for infection. Observe for signs & sx's of anaphylaxis. Monitor bowel function. PO: Administer w/o regard to food & w/ a full glass of water, at the same time QD. Products or foods containing calcium, magnesium, aluminum, iron, or zinc should not be ingested for 6 hr before and 2 hr after administration. If gastric irritation occurs, may be administered w/ meals. Encourage pt to maintain a fluid intake of at least 1500– 2000 mL/day. Caution pt to use sunscreen & protective clothing to during & for 5 days after therapy. Obtain specimens for c+s before initiating therapy.
Generic: labetalolrand: Trandate¤harmacological: Therapeutic: antianginals,antihypertensivesUsual 'ose:¤ (±dults):100 mg TT©U' initiþlly, mþy Ěĩ ↑ Ěy 100 mg TT©U' q 2– 3 Ģþys prn (usuþlrþngĩ 400– 800 mg/Ģþy in 2– 3 ĢiviĢĩĢ Ģosĩs; Ģosĩs up to 1.2– 2.4.TTTV (±dults):20 mg (0.25 mg/kg) initiþlly, þĢĢitionþlĢosĩs of 40– 80 mg mþy Ěĩ givĩn q 10 min prn (sÈtýtsþx 300 mg totþl Ģosĩ) or 2 mg/min infusion (rþngĩ 50– 300 mg totþlĢosĩ rĩquirĩĢ).±!TTTT uS:STTT'F FFFF!TS:TTTu'TTT!±TTTT uS:! uTR±TTTu'TTT!±TTTT uS:ii± TFST ! uSTTT'FR±TTTT uS:uURSTTTuG ! uSTTT'FR±TTTT uS:Pregnancy Category C, uncompensated HF, pulmonary edema, cardiogenic shock, bradycardia or heart block OB: May cause fetal/neonatal bradycardia, hypotension, hypoglycemia, or respiratory depression; Lactation: Usually compatible with breast feeding Pedi: Limited data available. Mgmt of HTNBlocks stimulation of beta1 (myocardial)- and beta2 (pulmonary, vascular, and uterine)-adrenergic receptor sites. Also has alpha1-adrenergic blocking activity, which may result in more orthostatic hypotension. Therapeutic Effects: Decreased BPFatigue, weakness, orthostatic hypotension, increase sensitivity to cold, ED, bronchospasm, wheezing. May cause ↑ BUN, serum lipoprotein, K+, triglyceride, and uric acid levels. May cause ↑ ANA titers. May cause ↑ in blood glucose levels. May cause ↑ serum alkaline phosphatase, LDH, AST, and ALT levels Monitor BP & pulse frequently during dose adjustment and periodically during therapy. Hold dose and call HCP if pulse <50.

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture